Clinical value of ¹⁸F-FDG-positron emission tomography in follicular lymphoma

Czech version

Authors: A. Janíková ¹; K. Bolčák ²; J. Mayer ¹; D. Néméthová ³; J. Staníček ²
Authors‘ workplace: Interní hematoonkologická klinika FN Brno, 2Oddělení nukleární medicíny Masarykova onkologického ústavu Brno, 3Institut biostatistiky a analýz Lékařská a Přírodovědecká fakulta Masarykovy univerzity Brno ¹
Published in: Transfuze Hematol. dnes,13, 2007, No. 3, p. 117-125.
Category: Comprehensive Reports, Original Papers, Case Reports

Overview

Aim:
To evaluate the role of ¹⁸F-FDG-positron emission tomography (PET) in the staging and restaging of follicular lymphoma (FL). PET appears to be highly sensitive and specific in the high-grade lymphoma, by contrast its usefulness in FL has not been clearly defined.

Methods:
127 PET scans were performed in 100 patients with FL in a retrospective study. Pathological PET-activity and standard computer tomography (CT) staging were compared in 56 patients before treatment. In the frame of restaging PET was performed in 71 patients (87 % treated by conventional therapy). Progression free survivals (PFS) of PET-positive and PET-negative patients were compared.

Results:
in comparison with CT and clinical examination, PET identified larger involvement in 30/56 patients, smaller in 7/56 and the same extension of FL was found in 15/56 patients. 4 patients revealed discordant foci visible only on PET and simultaneous lymphadenopathy on CT without PET activity (p<0,001). 15 patients with larger involvement by PET were essentially upstaged (from stage 0-2 to 3-4). Including the results of trephine biopsy the stage was substantially changed in 13/56 (23 %) patients. 56/71 patients were PET-negative after the treatment, 9 (16%) relapsed in median 10 months, 47 remained in remission at median follow-up of 19 months. 11/71 patients were PET-positive after the treatment, 9 (82 %) relapsed in median of 6 months. All of 4/71 patients with undetermined PET-positivity (SUV ±2,0) are in long-term remission at median follow-up of 39 months. PFS of the PET-negative patients was significantly longer in comparison with the PET-positive patients (p<0,001).

Conclusion:
PET may contribute to the management of follicular lymphoma patients. PET in the staging can substantially change the treatment strategy. PET-positivity after the treatment predicts high risk of early relapse and can identify patients with poor prognosis.

Key words:
¹⁸F-FDG-PET, follicular lymphoma, grading, staging, prognosis

Sources

1. Jerusalem G, Hustinx R, Beguin Y, et al. The value of positron emission tomography (PET) imaging in disease staging and therapy assessment. Ann Oncol 2002; 13 (Suppl 4): 227–34.

2. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006; 354: 496–507.

3. Newman JS, Francis IR, Kaminski MS, et al. Imaging of lymphoma with PET 2-[F-18]-fluoro-2-deoxy-D-glucose: Correlation with CT. Radiology 1994; 90: 111–6.

4. Moog F, Bangerter M, Diederichts CG, et al. Role of whole-body 2-[F-18]-fluoro-2-deoxy-D-glucose (FDG) PET in nodal staging. Radiology 1997; 203: 795–800.

5. Stumpe KD, Urbinelli M, Steinert HC, et al. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: Effectiveness and comparison with computed tomography. Eur J Nucl Med 1998; 25: 721–8.

6. Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003; 101: 3875–3876.

7. Jerusalem G, Beguin Y, Fassotte MF, et al. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin’s lymphoma. Haematologica 2000; 85: 613–618.

8. Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 flurodeoxyglucose ([18F] FDG) after first-line chemotherapy in Non-Hodgkin’s lymphoma: is ([ 18F] FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001; 19: 414–419.

9. Spaepen K, Stroobants S, Verhoef G, et al. Positron emission tomography with [18F] FDG for therapy response monitoring in lymphoma patiens. Eur J Nucl Med 2003; 30 (Suppl 1): S97–S105.

10. Bangerter M, Moog F, Buchmann I, et al. Whole-body 2-[F-18]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin’s disease. Ann Oncol 1998; 9: 1117–22.

11. Hernandez-Maraver D, Hernadez-Navarro F, Gomez-Leon N, et al. Positron emission tomography/computed tomography diagnostic accuracy in lymphoma. Br J Haematol 2006; 135(3): 293–302.

12. Hoh CK, Glaspy J, Rosen P, et al. Whole-body FDG-PET imaging for staging of Hodgkin’s disease and lymphoma. J Nucl Med 1997; 38: 343–8.

13. Schot BW, Zijlstra JM, Sluiter WJ, et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in reccuring lymphoma. Blood 2007; 109: 486–91.

14. Zinzani PL, Magagnoli M, Chierichetti F, et al. The role of positron emission tomography (PET) in the management of lymphoma patiens. Ann Oncol 1999; 10: 1181–1184.

15. Hicks RJ. The evolving role of fluorodeoxyglucose positron emission tomography (FDG-PET) in lymphoma: how do we reconcile conflicting results in the era of evidence-based medicine? Leuk Lymphoma 2006; 47: 2008–10.

16. JerusalemG, Beguin Y, Najjar F, et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin’s lymphoma (NHL). Ann Oncol 2001; 12: 825–830.

17. Karam M, Novak L, Cyriac J, et al. Role of fluorine-18 fluorodeoxyglucose positron emission tomography scan in the evaluation and follow-up of patiens with low-grade lymphomas. Cancer 2006; 107: 175–83.

18. Wöhrer S, Jaeger U, Kletter K, et al. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann Oncol 2006; 17: 780–784.

19. Jerusalem G, Warland V, Najjar F, et al. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin’s disease and non-Hodgkin’s lymphoma. Nucl Med Commun 1999; 20: 13–20.

20. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: Consensus of the imaging subcomitee of international harmonization project in lymphoma. J Clin Oncol 2007; 25: 571–578.

21. Blum RH, Seymour JF, Wirth A, et al. Frequent impact of [18F] fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin’s lymphoma. Clin Lymphoma 2003; 4(1): 43–9.

22. Svoboda J, Andreadis C, Elstrom R, et al. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant 2006; 38(3): 211–6.

23. Kahn ST, Flowers C, Lechovwicz MJ, et al. Value of PET restaging after chemotherapy for non-Hodgkin’s lymphoma: Implications for consolidation radiotherapy. Int J Radiat Oncol Biol Phys 2006; 66(4): 961–5.